Publications by authors named "Chunye Huang"
Article Synopsis
- * Recent studies suggest that MDM2 affects the immune environment around tumors, and its dysregulation may hinder the effectiveness of immunotherapies like PD-1/PD-L1 inhibitors.
- * Combining MDM2 inhibitors with existing immunotherapies shows potential in improving treatment outcomes for tumors that overexpress or amplify MDM2.
Hippo-Yes-associated protein 1 (YAP1) plays an important role in gastric cancer (GC) progression; however, its regulatory network remains unclear. In this study, we identified Copine III (CPNE3) was identified as a novel direct target gene regulated by the YAP1/TEADs transcription factor complex. The downregulation of CPNE3 inhibited proliferation and invasion, and increased the chemosensitivity of GC cells, whereas the overexpression of CPNE3 had the opposite biological effects.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the role of TMEM160 in regulating PD-L1 expression in colorectal cancer (CRC), revealing that TMEM160 stabilizes PD-L1 and prevents its degradation.
- Phenotypic and animal model experiments showed that TMEM160 enhances CRC cell proliferation, invasion, and resistance to treatment, while its absence decreased these abilities and improved the effectiveness of immune responses against tumor cells.
- Clinical analysis demonstrated a significant correlation between TMEM160 and PD-L1 levels in CRC tissues, suggesting that high TMEM160 expression may impact patient outcomes negatively by correlating with low immune response indicators.
Article Synopsis
- Fibroblast growth factors (FGFs) and their receptors (FGFRs) are important for how cells grow and how new blood vessels form. When these systems don't work properly, it can lead to cancer.
- Researchers are exploring the idea of using FGFR inhibitors (which block FGFR) together with immunotherapy (a type of treatment that helps the immune system fight cancer) to make treatments more effective.
- The study looks at how FGFs and FGFRs influence the environment around tumors and how combining FGFR inhibitors with immunotherapy could help patients with certain types of cancer respond better to treatment.
According to previous reports,10-16% of patients with clinically advanced cholangiocarcinoma develop FGFR2 fusions or rearrangements. Treatment with FGFR2-specific inhibitors (tyrosine kinase inhibitors, TKIs) has proven effective for patients with cholangiocarcinoma. In this study, we report a case of advanced cholangiocarcinoma, in which the patient was unable to tolerate the adverse effects of standard first-line chemotherapy.
View Article and Find Full Text PDFThe importance of the Hippo-Yes-associated protein 1 (YAP1) pathway in gastric carcinogenesis and metastasis has attracted considerable research attention; however, the regulatory network of YAP1 in gastric cancer (GC) is not completely understood. In this study, ubiquitin-specific peptidase 49 (USP49) was identified as a novel deubiquitinase of YAP1, knockdown of USP49 inhibited the proliferation, metastasis, chemoresistance, and peritoneal metastasis of GC cells. Overexpression of USP49 showed opposing biological effects.
View Article and Find Full Text PDFF-box and WD repeat domain-containing 5 (FBXW5), with WD40 repeats, can bind to the PPxY sequence of the large tumor suppressor kinases 1/2 (LATS1/2) kinase domain, resulting in ubiquitination. Ubiquitination and the subsequent degradation of LATS1/2 abrogate the Hippo pathway and worsen gastric cancer (GC). However, the effects and molecular mechanisms of FBXW5 in GC remain unexplored.
View Article and Find Full Text PDFPurpose: Programmed death ligand 1 (PD-L1) is widely used for predicting immune checkpoint inhibitors but has a limited effect on predicting clinical response. The aim of this study was to examine the prognostic value and PD-1 inhibitor therapeutic efficiency of SNX20 in lung adenocarcinoma.
Methods: We evaluated the mRNA and protein expression levels of SNX20 and PD-L1 and confirmed their predictive role in clinical response to anti-PD-1 therapy in 56 patients with advanced, refractory lung adenocarcinoma treated with PD-1 inhibitors.